Search clinical trials for: anti-PD-L1 antibody

Total 2272 results

Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Lymphoma | Tumor, Solid

China
City of Hope Medical Center
National Cancer Institute (NCI); Imugene Limited

Active, not recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
University of Colorado, Denver
AstraZeneca

Withdrawn

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
Zhongnan Hospital

Recruiting

Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Baodong Qin

Unknown

Effect of Chemotherapy on PD-L1 in NSCLC

Chemotherapy | Immunotherapy | PD-L1

China
Tatarstan Cancer Center

Unknown

Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer

Hereditary Breast Cancer

Russian Federation
Shanghai Zhongshan Hospital

Recruiting

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Cholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4

China
Hoffmann-La Roche

Completed

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell

United Kingdom, Czechia, Germany, Poland, Spain, Switzerland
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Solid Tumor | Metastatic Cancer | Locally Advanced Solid Tumor

United States
Leiden University Medical Center
Radboud University Medical Center; AstraZeneca; University Medical Center Groningen and other collaborators

Active, not recruiting

Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC)

Uterine Neoplasms | Endometrial Neoplasms | Endometrium Cancer

Netherlands
Medical University of Vienna

Unknown

CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients

Non Small Cell Lung Cancer

Austria
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Head and Neck Cancer

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NSCLC | Advanced Solid Tumor

United States, China
University Hospital, Angers

Completed

Exosomes Implication in PD1-PD-L1 Activation in OSAS (ExoSAS)

Cancer | Sleep Apnea Syndromes, Obstructive

France
Dragonboat Biopharmaceutical Company Limited
Shanghai East Hospital

Unknown

Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors

Advanced Tumors

China
Yale University

Completed

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Breast Neoplasms

United States
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Advanced Lung Carcinoma
Lars Møller Pedersen

Completed

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

Follicular Lymphoma

Denmark
SparX Biotech(Jiangsu) Co., Ltd.

Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303)

Solid Tumor | CRC | HNSCC | RCC

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

Safety Issues | Effect Increased
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Lee's Pharmaceutical Limited

Not yet recruiting

Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

High-grade Osteosarcoma
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Extranodal NK/T Cell Lymphoma, Nasal Type

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Cervical Cancer | Advanced Solid Tumor

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
Bio-Thera Solutions
Sun Yat-sen University

Recruiting

BAT7104 Injection in Patients With Advanced Malignant Tumors.

Advanced Malignant Tumor

China
Peking Union Medical College Hospital

Recruiting

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Hepatocellular Carcinoma

China
Dragonboat Biopharmaceutical Company Limited
Fudan University

Recruiting

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

Bladder Cancer | Renal Carcinoma | Advanced Penile Carcinoma

China
Herlev and Gentofte Hospital
University of Copenhagen

Completed

A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma

Basal Cell Carcinoma

Denmark
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
Inge Marie Svane

Completed

Dual Vaccine Trial in Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia

Denmark
Lene Meldgaard Knudsen

Completed

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Multiple Myeloma

Denmark
Megan Daly, MD
EMD Serono

Completed

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Metastatic Non-small Cell Lung Cancer (NSCLC)

United States
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
The First Affiliated Hospital of Zhengzhou University

Recruiting

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer (AIPAAIAEC)

Esophageal Neoplasms

China
Chinese PLA General Hospital
LinkDoc Technology (Beijing) Co. Ltd.

Unknown

A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China

Search clinical trials for: anti-PD-L1 antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations